Compared to Estimates, Neogen (NEOG) Q2 Earnings: A Look at Key Metrics

Core Insights - Neogen (NEOG) reported a revenue of $224.69 million for the quarter ended November 2025, reflecting a year-over-year decline of 2.8% and an EPS of $0.10, down from $0.11 in the same quarter last year. However, the revenue exceeded the Zacks Consensus Estimate of $209.74 million by 7.13% [1] Revenue Performance - Animal Safety revenues were $59.14 million, surpassing the average estimate of $56.56 million, but showing a year-over-year decline of 11.8% [4] - Food Safety revenues reached $165.55 million, exceeding the average estimate of $153.19 million, with a slight year-over-year increase of 0.8% [4] - Specific revenue breakdowns include: - Indicator Testing, Culture Media & Other: $86.11 million, exceeding estimates of $76.36 million, with a year-over-year increase of 3.4% [4] - Life Sciences under Animal Safety: $1.45 million, below the estimate of $1.6 million, reflecting an 11% decline year-over-year [4] - Veterinary Instruments & Disposables: $13.68 million, below the estimate of $15.68 million, showing a year-over-year decline of 20.8% [4] - Animal Care & Other: $8.89 million, below the estimate of $10.41 million, with a year-over-year decline of 9% [4] - Natural Toxins & Allergens: $20.44 million, slightly above the estimate of $19.1 million, with a year-over-year change of -0.3% [4] - Genomics Services under Animal Safety: $17.18 million, significantly above the estimate of $4.83 million [4] - Genomics Services under Food Safety: $6.26 million, below the estimate of $13.93 million [4] - Biosecurity Products under Food Safety: $4.57 million, below the estimate of $8.74 million [4] - Bacterial & General Sanitation: $44.92 million, exceeding the estimate of $39.28 million, with a year-over-year increase of 5.6% [4] - Biosecurity Products under Animal Safety: $17.93 million, slightly below the estimate of $18.7 million [4] Stock Performance - Neogen's shares have returned +5.7% over the past month, outperforming the Zacks S&P 500 composite, which saw a +0.9% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]